Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Sinopharm is a leading pharmaceutical and healthcare conglomerate in China, best known globally for developing and distributing the BBIBP-CorV (Sinopharm BIBP COVID-19 vaccine), which showed 78.1% efficacy against symptomatic COVID-19 and 100% efficacy against severe cases in Phase 3 trials. The company has a broad and diversified portfolio spanning vaccines, blood products, small molecules, and medical devices, with commercialized products distributed worldwide. Its COVID-19 vaccine has received WHO emergency use authorization and is widely used internationally.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Sinopharm Holding.